What’s the latest with investigational drugs for soft tissue sarcoma?

Cojocaru, Elena; Napolitano, Andrea; Fisher, Cyril; Huang, Paul H.; Jones, Robin L.; Thway, Khin

doi:10.1080/13543784.2022.2152324

Cited by 4 publications

(5 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, platelets, neutrophils, lymphocytes, and monocytes of blood samples were recorded before the first administration. Based on previous research findings, the critical thresholds have been set as follows: absolute lymphocyte count (ALC) (cells/mm 3 ) at 1500 (Shimizu et al 2020 ), absolute neutrophil count (ANC) (cells/mm 3 ) at 4000 (Cojocaru et al 2022 ), neutrophil-to-lymphocyte ratio (NLR) at 3.5 (de Juan Ferré et al 2021 ), platelet-to-lymphocyte ratio (PLR) at 200 (von Mehren et al 2020 ), and lymphocyte-to-monocyte ratio (LMR) at 3.0 (Smrke et al 2020 ).…”

Section: Methodsmentioning

confidence: 99%

Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy

Zheng,

Liu,

Liu

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Objective The purpose of this study was to compare the antitumor efficacy of anlotinib with gemcitabine-based chemotherapy as subsequent treatment regimens in patients with advanced non-specific soft tissue sarcoma (STS) after the failure of anthracycline-based chemotherapy. Methods Patients diagnosed with advanced STS who were treated with either anlotinib or gemcitabine-based chemotherapy between May 2009 and May 2023 in our center were eligible. All patients experienced disease progression or recurrence after the anthracycline-based chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were disease control rate (DCR), overall survival (OS) and safety. Results We included 49 patients receiving anlotinib and 45 patients receiving gemcitabine-based chemotherapy. The median follow-up time was 76.9 weeks (range 2.9–678.9 weeks). The DCR (65.3% vs. 57.8%; p = 0.610), PFS (24.0 weeks vs. 18.6 weeks; p = 0.669) and OS (79.4 weeks vs. 87.0 weeks; p = 0.471) of anlotinib and gemcitabine-based chemotherapy indicated similar clinical efficacy. Moreover, exploratory subgroup analyses showed that patients with STS originating from limbs and trunk were inclined to benefit from anlotinib treatment (median PFS: 31.3 weeks vs. 12.4 weeks; p = 0.045). ECOG PS was an independent predictor of the PFS [Hazard Ratio (HR) 0.31; 95% confidence interval (CI) 0.11–0.85; p = 0.023] and OS (HR 0.26, 95%CI 0.10–0.70; p = 0.008) in the anlotinib group. While neutrophil-to-lymphocyte ratio (NLR) was an independent prognostic factor of the PFS (HR 0.33, 95%CI 0.11–0.98; p = 0.045) in the gemcitabine-based chemotherapy group. The incidence of grade 3 or higher related AEs in anlotinib and gemcitabine-based chemotherapy was 20.4% (n = 10) and 20.0% (n = 9), respectively. Conclusion Our research suggested that anlotinib and gemcitabine-based chemotherapy showed similar clinical efficacy and safety in the subsequent treatment of advanced STS after the failure of anthracycline-based chemotherapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy

Zheng,

Liu,

Liu

et al. 2024

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Concerning the previous description, cancers with high heterogeneity can render traditional treatment ineffective in some cases due to the diverse immune characteristics of malignant tumors. Developing new therapeutic strategies based on these immune characteristics is a feasible approach 165 . While immunotherapy has been integrated into the treatment of carcinomas and sarcomas, the response to it varies significantly 143,164,166 .…”

Section: Clinical Implication Of Tls In Malignant Tumorsmentioning

confidence: 99%

“…Developing new therapeutic strategies based on these immune characteristics is a feasible approach. 165 While immunotherapy has been integrated into the treatment of carcinomas and sarcomas, the response to it varies significantly. 143 , 164 , 166 Research across different tumors has demonstrated that TLSs can serve as both a prognostic marker and an intervention target.…”

Section: Clinical Implication Of Tls In Malignant Tumorsmentioning

confidence: 99%

Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications

Wang,

et al. 2024

MedComm

View full text Add to dashboard Cite

Cancer is a major cause of death globally, and traditional treatments often have limited efficacy and adverse effects. Immunotherapy has shown promise in various malignancies but is less effective in tumors with low immunogenicity or immunosuppressive microenvironment, especially sarcomas. Tertiary lymphoid structures (TLSs) have been associated with a favorable response to immunotherapy and improved survival in cancer patients. However, the immunological mechanisms and clinical significance of TLS in malignant tumors are not fully understood. In this review, we elucidate the composition, neogenesis, and immune characteristics of TLS in tumors, as well as the inflammatory response in cancer development. An in‐depth discussion of the unique immune characteristics of TLSs in lung cancer, breast cancer, melanoma, and soft tissue sarcomas will be presented. Additionally, the therapeutic implications of TLS, including its role as a marker of therapeutic response and prognosis, and strategies to promote TLS formation and maturation will be explored. Overall, we aim to provide a comprehensive understanding of the role of TLS in the tumor immune microenvironment and suggest potential interventions for cancer treatment.

show abstract

“…Despite the low incidence of STSs, hundreds of thousands of new STS cases are diagnosed annually worldwide, and approximately half of them eventually progress to advanced stages ( Corey et al, 2014 ; Bhatt et al, 2016 ; Hung et al, 2019 ; Yang et al, 2019 ). Currently, chemotherapy is the first-line treatment for advanced STSs ( Cojocaru et al, 2022 ; de Juan Ferre et al, 2021 ; von Mehren et al, 2020 ). Anthracyclines (mainly doxorubicin) were found to be effective against STSs in 1973 ( Tan et al, 1973 ; Sritharan and Sivalingam, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

“…Although some drugs have shown good efficacy in individual subtypes, none have exceeded the efficacy and safety achieved by doxorubicin for STSs. To date, doxorubicin remains the first-line chemotherapeutic drug for STSs ( Cojocaru et al, 2022 ; de Juan Ferre et al, 2021 ; von Mehren et al, 2020 ; Smrke et al, 2020 ; Smolle et al, 2020 ; Meyer and Seetharam, 2019 ; Yang et al, 2022 ; Gronchi et al, 2017 ). Selecting second- or higher-line drugs for advanced STS remains a challenge ( Frezza et al, 2017 ; Kim et al, 2019 ; Haddox and Riedel, 2020 ; Younger et al, 2021 ; Kojima et al, 2022 ).…”

Section: Introductionmentioning

confidence: 99%

Chemotherapeutic drugs for soft tissue sarcomas: a review

Tian

Yao

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Despite the low incidence of soft tissue sarcomas (STSs), hundreds of thousands of new STS cases are diagnosed annually worldwide, and approximately half of them eventually progress to advanced stages. Currently, chemotherapy is the first-line treatment for advanced STSs. There are difficulties in selecting appropriate drugs for multiline chemotherapy, or for combination treatment of different STS histological subtypes. In this study, we first comprehensively reviewed the efficacy of various chemotherapeutic drugs in the treatment of STSs, and then described the current status of sensitive drugs for different STS subtypes. anthracyclines are the most important systemic treatment for advanced STSs. Ifosfamide, trabectedin, gemcitabine, taxanes, dacarbazine, and eribulin exhibit certain activities in STSs. Vinca alkaloid agents (vindesine, vinblastine, vinorelbine, vincristine) have important therapeutic effects in specific STS subtypes, such as rhabdomyosarcoma and Ewing sarcoma family tumors, whereas their activity in other subtypes is weak. Other chemotherapeutic drugs (methotrexate, cisplatin, etoposide, pemetrexed) have weak efficacy in STSs and are rarely used. It is necessary to select specific second- or above-line chemotherapeutic drugs depending on the histological subtype. This review aims to provide a reference for the selection of chemotherapeutic drugs for multi-line therapy for patients with advanced STSs who have an increasingly long survival.

show abstract

What’s the latest with investigational drugs for soft tissue sarcoma?

Cited by 4 publications

References 116 publications

Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy

Efficacies of anlotinib monotherapy versus gemcitabine-based chemotherapy for patients with advanced soft tissue sarcoma after the failure of anthracycline-based chemotherapy

Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications

Chemotherapeutic drugs for soft tissue sarcomas: a review

Contact Info

Product

Resources

About